BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
Bionexus Gene Lab (US:BGLC) Globenewswire·2025-07-30 20:00KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. ("BGLC", Nasdaq:BGLC) and FidelionDiagnosticsPteLtd, a Singaporean company ("Fidelion") today announced the signing of a term sheet for a strategic, cross-equity partnership that the parties are calling a "DeepSeek-class leap" for liquid biopsy cancer monitoring and AI-driven biotechnology. This builds on BGLC's mission to be a global leader in liquid biopsies, and tumor naïve oncology solutions. Under the term sheet, BGLC wil ...